Related Experiment Video
Updated: Apr 21, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Precision medicine for prostate cancer
Myria Galazi1, Alejo Rodriguez-Vida, Tony Ng
1Department of Medical Oncology, Guy's Hospital, London, SE1 9RT, UK.
Abstract:
Metastatic castration-resistant prostate cancer remains a lethal disease despite considerable progress in systemic therapy over the past decade. The recent advances in genomic sequencing have improved the molecular classification of prostate cancer. The translation of genomic data into clinically relevant prognostic and predictive biomarkers to guide therapy is still in its infancy and therapies for castration-resistant prostate cancer are still used empirically. We discuss these genomic aberrations in more detail, focusing on androgen receptor signaling, ETS transcription factor gene rearrangements and PTEN loss. The incorporation of this genomic data within early phase clinical trials is evolving and may prove significant in advancing personalized care in prostate cancer.
Insights
Metastatic castration-resistant prostate cancer treatment is improving with genomic insights. Understanding key genetic changes like androgen receptor signaling can guide future personalized therapies for this lethal disease.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) is a significant cause of cancer mortality.
- Despite advances, mCRPC treatment often relies on empirical approaches.
- Genomic sequencing has enhanced prostate cancer molecular classification.
Purpose of the Study:
- To review key genomic aberrations in prostate cancer.
- To discuss the potential of genomic data in guiding mCRPC therapy.
- To highlight the evolving role of genomic information in clinical trials.
Main Methods:
- Literature review and discussion of genomic alterations.
- Focus on androgen receptor signaling, ETS gene rearrangements, and PTEN loss.
- Examination of the integration of genomic data in early-phase clinical trials.
Main Results:
- Genomic sequencing reveals critical aberrations in prostate cancer.
- Androgen receptor signaling, ETS rearrangements, and PTEN loss are frequently observed.
- Translating genomic findings into predictive biomarkers is still developing.
Conclusions:
- Genomic data offers a pathway to personalized prostate cancer care.
- Further integration of genomic insights into clinical trials is crucial.
- Personalized therapeutic strategies hold promise for improving outcomes in mCRPC.
